Trial Profile
In Vivo Imaging of the Effect of Fulvestrant on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Tumour Lesions Using FES-PET
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Pharmacodynamics
- 15 Sep 2014 New trial record
- 15 Oct 2013 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.